Liens UNIL

FR EN

Unisciences

Vous êtes ici: UNIL > Unisciences

Recherche
- Recherche
- Afficher les données
  de à

Michel Burnier

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil

907 publications

... | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | ...

2007

L'éplérénone: un antagoniste sélectif du récepteur aux minéralocorticoïdes

Vogt B., Waeber B., Burnier M., 2007. Forum Médical Suisse, 7 pp. 351-354.

[URN][serval:BIB_22A42A83B933]

Microalbuminuria, but not cystatin C, is associated with carotid atherosclerosis in middle-aged adults.

Rodondi N., Yerly P., Gabriel A., Riesen W.F., Burnier M., Paccaud F., Bovet P., 2007. Nephrology, Dialysis, Transplantation, 22 (4) pp. 1107-1114. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_E61A744996D4]

Oxidized low-density lipoproteins activate CD4+ T cell apoptosis in patients with end-stage renal disease through Fas engagement

Meier P., Spertini F., Blanc E., Burnier M., 2007. Journal of the American Society of Nephrology, 18 (1) pp. 331-42.

[DOI][WoS][Pmid][serval:BIB_962BA8FD4BF4]

Prevalence of elevated blood pressure and association with overweight in children of a rapidly developing country.

Chiolero Arnaud, Madeleine George, Gabriel Anne, Burnier Michel, Paccaud Fred, Bovet Pascal, 2007. Journal of Human Hypertension, 21 (2) pp. 120-127. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_BAC0AE93A687]

Prevalence of hypertension in schoolchildren based on repeated measurements and association with overweight.

Chiolero Arnaud, Cachat François, Burnier Michel, Paccaud Fred, Bovet Pascal, 2007. Journal of Hypertension, 25 (11) pp. 2209-2217. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_F6FA010204DB]

Reactive rise in blood pressure upon cuff inflation: cuff inflation at the arm causes a greater rise in pressure than at the wrist in hypertensive patients.

Charmoy A., Würzner G., Ruffieux C., Hasler C., Cachat F., Waeber B., Burnier M., 2007. Blood Pressure Monitoring, 12 (5) pp. 275-280. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_EBE3067C147F]

Renal sodium handling and nighttime blood pressure.

Burnier M., Coltamai L., Maillard M., Bochud M., 2007. Seminars in nephrology, 27 (5) pp. 565-71. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_0181AA69E78A]

The association of aldosterone with obesity-related hypertension and the metabolic syndrome.

Vogt B., Bochud M., Burnier M., 2007. Seminars in nephrology, 27 (5) pp. 529-537. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_5445B36DACCA]

2006

Medication adherence and persistence as the cornerstone of effective antihypertensive therapy

Burnier M., 2006/11. American Journal of Hypertension, 19 (11) pp. 1190-6.

[URN][DOI][WoS][Pmid][serval:BIB_5A66ED69F521]

Association between arterial properties and renal sodium handling in a general population

Seidlerova J., Staessen J. A., Maillard M., Nawrot T., Zhang H., Bochud M., Kuznetsova T., Richart T., Van Bortel L. M., Struijker-Boudier H. A. et al., 2006/10. Hypertension, 48 (4) pp. 609-15. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_64B99068D9CC]

Physicians' estimates of the 10 year cardiovascular risk in hypertensive patients: an evaluation in primary care physicians in training.

Senn M., Favrat B., Vaucher P., Burnier M., 2006/09/16. Swiss medical weekly, 136 (37-38) pp. 603-608. Peer-reviewed.

[URN][WoS][Pmid][serval:BIB_34F3B47F2169]

Antihypertenseurs de premiere intention: les betabloquants sous pression! [Antihypertensive agents used as first line agents: beta-blockers under pressure]

Burnier M., Pechere A., Waeber B., 2006/09. Revue Médicale Suisse, 2 (78) pp. 2019-20.

[Pmid][serval:BIB_180D15622E19]

La tercanidipine, un inhibiteur calcique de troisieme generation. Quels avantages? [Lercanidipine, a third generation calcium antagonist. Which advantages?]

Meier P., Burnier M., 2006/09. Revue Médicale Suisse, 2 (78) pp. 2047-50, 2052-3.

[Pmid][serval:BIB_FBB719F76B34]

Spotlight on renin. The renin-angiotensin-aldosterone system and metabolic syndrome

Burnier M., 2006/09. Journal of the Renin-Angiotensin-Aldosterone System, 7 (3) p. 184.

[DOI][WoS][Pmid][serval:BIB_197BDEAC3CF7]

Response to Compliance With Hypertension Therapy: Why Standards Are Needed

Halpern M. T., Khan Z. M., Schmier J. K., Burnier M., Caro J. J., Cramer J., Daley W. L., Gurwitz J., Hollenberg N. K., 2006/08. Hypertension, 48 (4) pp. E17.

[DOI][WoS][Pmid][serval:BIB_8D521D04D4C8]

Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction--an analysis of the EPHESUS study from a Swiss perspective

Szucs T. D., Holm M. V., Schwenkglenks M., Zhang Z., Weintraub W. S., Burnier M., Erne P., 2006/06. Cardiovascular Drugs and Therapy, 20 (3) pp. 193-204.

[DOI][WoS][Pmid][serval:BIB_117847A66E6D]

Differential persistence with initial antihypertensive therapies: a clue for understanding the needs of hypertensive patients.

Waeber B., Burnier M., 2006/06. Journal of Hypertension, 24 (6) pp. 1021-1022. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_D437C2FE0895]

Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data

Halpern M. T., Khan Z. M., Schmier J. K., Burnier M., Caro J. J., Cramer J., Daley W. L., Gurwitz J., Hollenberg N. K., 2006/06. Hypertension, 47 (6) pp. 1039-48.

[DOI][WoS][Pmid][serval:BIB_52317BBF59AE]

Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland.

Palmer A.J., Roze S., Valentine W.J., Ray J.A., Frei A., Burnier M., Hess B., Spinas G.A., Brändle M., 2006/05/27. Swiss medical weekly, 136 (21-22) pp. 346-352. Peer-reviewed.

[URN][WoS][Pmid][serval:BIB_387B5794018D]

Increased carotid intima-media thickness in the absence of atherosclerotic plaques in an adult population with Fabry disease.

Barbey F., Brakch N., Linhart A., Jeanrenaud X., Palecek T., Bultas J., Burnier M., Hayoz D., 2006/04. Acta Paediatrica, 95 (451) pp. 63-68.

[DOI][WoS][Pmid][serval:BIB_90806391FFBA]

Initial combination therapy with olmesartan/hydrochlorothiazide in moderate-to-severe hypertension

Rump L. C., Ambrosioni E., Burnier M., Horl W., Rabelink A. J., 2006/04. Journal of Human Hypertension, 20 (4) pp. 299-301.

[DOI][WoS][Pmid][serval:BIB_3E4CA14675DC]

Proximal tubular function and salt sensitivity.

Burnier M., Bochud M., Maillard M., 2006/04. Current Hypertension Reports, 8 (1) pp. 8-15. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_91F218D6F5BC]

Effects of selective angiotensin II and beta1-receptor blockade on renal haemodynamics and sodium handling during orthostatic stress in healthy individuals.

Wuerzner G., Burnier M., 2006/03. Journal of Hypertension. Supplement, 24 (1) pp. S89-S93.

[DOI][WoS][Pmid][serval:BIB_31C4BAC11CF6]

Insuffisance rénale chronique: quel régime [Chronic renal failure: what diet?].

Teta D., Phan O., Halabi G., Blancheteau A., Cheseaux M., Roulet M., Burnier M., 2006/03. Revue Médicale Suisse, 2 (55) pp. 566-569.

[Pmid][serval:BIB_65D9D3D9B27B]

Nutrition et insuffisance renale chronique: un casse-tete! [Nutrition and chronic renal failure: a puzzle!]

Martin P. Y., Burnier M., 2006/03. Revue Médicale Suisse, 2 (55) p. 563.

[Pmid][serval:BIB_0C086158B525]

Obesite: quel impact sur la fonction renale ? [Obesity: what impact on renal function?]

Mathieu C., Teta D., Vogt B., Burnier M., 2006/03. Revue Médicale Suisse, 2 (55) pp. 576-8, 580-1.

[Pmid][serval:BIB_BEC68FDF880F]

Wirtschaftlichkeit des Einsatzes von Irbesartan bei Patienten mit Typ-2 Diabetes, Hypertonie und Nephropathie in der Schweiz. [Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland]

Frei A., Palmer A. J., Burnier M., Hess B., 2006/03. Schweizerische Rundschau fur Medizin Praxis, 95 (11) pp. 401-8.

[Pmid][serval:BIB_4EC3A2E56B91]

Anemia and chronic kidney disease are associated with poor outcomes in heart failure patients.

Luthi J.C., Flanders W.D., Burnier M., Burnand B., McClellan W.M., 2006. BMC nephrology, 7 p. 3.

[URN][DOI][Pmid][serval:BIB_89AE09013B1C]

Association of CYP3A5 genotypes with blood pressure and renal function in African families.

Bochud M., Eap C.B., Elston R.C., Bovet P., Maillard M., Schild L., Shamlaye C., Burnier M., 2006. Journal of hypertension, 24 (5) pp. 923-9. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_2174105C05DE]

Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes

Burnier M., Zanchi A., 2006/01. Journal of Hypertension, 24 (1) pp. 11-25. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_D29795B7F19E]

Blutdrucksenkende Behandlung bei älteren Menschen

Burnier M., Meyer zu Starten A., Taddei S., 2006. pp. 961-968 dans M. Lemnitz (eds.) Handbuch des Fettstoffwechselstörungen, Schattauer GmbH.

[serval:BIB_3D1D5FE8798C]

Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition.

Barbey F., Brakch N., Linhart A., Rosenblatt-Velin N., Jeanrenaud X., Qanadli S., Steinmann B., Burnier M., Palecek T., Bultas J. et al., 2006. Arteriosclerosis, thrombosis, and vascular biology, 26 (4) pp. 839-44.

[DOI][WoS][Pmid][serval:BIB_C46A7B226B4E]

Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs

Maillard M., Burnier M., 2006/01. Expert Opinion on Drug Safety, 5 (1) pp. 83-94.

[DOI][WoS][Pmid][serval:BIB_CF24F7E57D71]

Do travelers really take their mefloquine malaria chemoprophylaxis? Estimation of adherence by an electronic pillbox.

Landry P., Iorillo D., Darioli R., Burnier M., Genton B., 2006. Journal of Travel Medicine, 13 (1) pp. 8-14. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_C792A4B4CBAC]

Hypertension artérielle. Traitement antihypertenseur: quelle pression cible et pour qui? [Antihypertensive therapy: who should be treated and to which target?]

Waeber B., Burnier M., 2006/01. Revue médicale suisse, 2 (48) pp. 123-4, 126-7.

[Pmid][serval:BIB_76A01EDB86D1]

Long-term management of antihypertensive therapy in general practice

Burnier M., Taddei S., Rhéaume C., 2006. pp. 25-40 dans H. R. Brunner (eds.) The Year of Hypertension, Clinical Publishing Ltd.

[serval:BIB_3BAAE01D832D]

Plasma aldosterone is independently associated with the metabolic syndrome.

Bochud M., Nussberger J., Bovet P., Maillard M.R., Elston R.C., Paccaud F., Shamlaye C., Burnier M., 2006. Hypertension, 48 (2) pp. 239-45. Peer-reviewed.

[URN][DOI][WoS][Pmid][serval:BIB_13433301EDF9]

Prevalence of hypertension and association with excess weight in children: preliminary results of a population-based study in Switzerland

Chiolero A., Cachat F., Burnier M., Paccaud F., Bovet P, 2006. p. 67 dans 14TH Annual EUPHA Meetings Politics, Policies and/or the Public's Health, European Journal of Public Health.

[WoS][serval:BIB_095B189FD6A2]

Retroperitoneal fibrosis, a true inflammatory disease: new insights in an old entity

Meier P., Rotman S., Blanc E., Burnier M., 2006. pp. 1-38 dans J. A. Pitzer (eds.) Progress in Inflammatory Research, Nova Science Publishers.

[serval:BIB_DCC35437B5C7]

The PPARgamma agonist pioglitazone modifies the vascular sodium-angiotensin II relationship in insulin-resistant rats.

Zanchi A., Perregaux C., Maillard M., Cefai D., Nussberger J., Burnier M., 2006. American journal of physiology. Endocrinology and metabolism, 291 (6) pp. E1228-34. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_95BC823E0AC8]

Would artificial neural networks implemented in clinical wards help nephrologists in predicting epoetin responsiveness?

Gabutti L., Lötscher N., Bianda J., Marone C., Mombelli G., Burnier M., 2006. BMC Nephrology, 7 p. 13. Peer-reviewed.

[URN][DOI][Pmid][serval:BIB_7BB0E536211D]

2005

OASIS-HT: design of a pharmacogenomic dose-finding study

Staessen J. A., Kuznetsova T., Acceto R., Bacchieri A., Brand E., Burnier M., Celis H., Citterio L., de Leeuw P. W., Filipovsky J. et al., 2005/10. Pharmacogenomics, 6 (7) pp. 755-75.

[DOI][WoS][Pmid][serval:BIB_9D065882841B]

Compliance in hypertension.

Burnier M., 2005/09. EDTNA/ERCA Journal, 31 (3) pp. 152-155.

[Pmid][serval:BIB_7B35E1C2FF33]

L'hyperuricemie dans l'hypertension arterielte: quelle implication? [Hyperuricemia in hypertension: any clinical implication?]

Deleaval P., Burnier M., 2005/09. Revue Médicale Suisse, 1 (32) pp. 2072-4, 2077-9.

[Pmid][serval:BIB_009947C73008]

Potassium supplementation reduces cardiac and renal hypertrophy independent of blood pressure in DOCA/salt mice

Wang Q., Domenighetti A. A., Pedrazzini T., Burnier M., 2005/09. Hypertension, 46 (3) pp. 547-54.

[DOI][WoS][Pmid][serval:BIB_717ABB8D4B3F]

Glucose-containing peritoneal dialysis fluids regulate leptin secretion from 3T3-L1 adipocytes

Teta D., Tedjani A., Burnier M., Bevington A., Brown J., Harris K., 2005/07. Nephrology, Dialysis, Transplantation, 20 (7) pp. 1329-35.

[URN][DOI][WoS][Pmid][serval:BIB_A442C9C6B35C]

Telmisartan/hydrochlorothiazide: a new fixed dose combination

Maillard M., Burnier M., 2005/05. Expert Review of Cardiovascular Therapy, 3 (3) pp. 375-86.

[DOI][Pmid][serval:BIB_B5484E4F47DF]

The safety of rofecoxib

Burnier M., 2005/05. Expert Opinion on Drug Safety, 4 (3) pp. 491-9.

[DOI][Pmid][serval:BIB_2BAE1CC97371]

Inhibiteurs selectifs de la cyclooxygenase 2 et facteurs de risque cardiovasculaires. [Selective COX-2 inhibitors and cardiovascular risk]

Meier P., Meyer zu Straten A., Burnier M., 2005/02. Revue Médicale Suisse, 1 (8) pp. 543-6, 549-50.

[Pmid][serval:BIB_FE5B079F270C]

The future of angiotensin II inhibition in cardiovascular medicine.

Meier P., Maillard M., Burnier M., 2005/02. Current Drug Targets. Cardiovascular and Haematological Disorders, 5 (1) pp. 15-30.

[WoS][Pmid][serval:BIB_7380FDB558EB]

Association between the CYP3A5 A698G polymorphism and blood pressure in individuals of east African descent

Eap Chin-Bin, Bochud Murielle, Elston Robert C., Bovet Pascal, Maillard Marc P., Burnier Michel, 2005. pp. MCV-042, p. 145 dans , CHUV Research Day.

[serval:BIB_846A5683065D]

Circadian variations in blood pressure : implications for chronotherapeutics

Hasler C., Burnier M., 2005. American Journal of Cardiovascular Drugs, 5 (1) pp. 7-15.

[Pmid][serval:BIB_10AB62CE8EB2]

Cuff inflation induces a greater reactive rise in blood pressure when placed at the arm than at the wrist in hypertensive patients

Charmoy A., Hassler C., Cachat F., Ruffieux C., Waeber B., Burnier M., 2005. pp. S37 dans 15th European Meeting on Hypertension, Journal of Hypertension.

[serval:BIB_4F7291741BAA]

Determinants of persistence in hypertensive patients treated with irbesartan: results of a postmarketing survey.

Burnier M., Hess B., Greminger P., Waeber B., 2005. BMC cardiovascular disorders, 5 (1) p. 13.

[URN][DOI][Pmid][serval:BIB_5CFC2009EB48]

Haben selektive COX-2-Hemmer unerwünschte renale und kardiovaskuläre Wirkungen [Do selective COX-2 inhibitors have adverse renal and cardiovascular effects?].

Mathieu C., Meier P., Meyer zu Starten A., Burnier M., 2005. Praxis, 94 (47) pp. 1851-1858.

[Pmid][serval:BIB_5BF09D2EFD14]

Heritability of renal function in hypertensive families of African descent in the Seychelles (Indian Ocean).

Bochud M., Elston R.C., Maillard M., Bovet P., Schild L., Shamlaye C., Burnier M., 2005. Kidney international, 67 (1) pp. 61-9. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_21B382C6A27A]

High heritability of ambulatory blood pressure in families of East African descent.

Bochud M., Bovet P., Elston R.C., Paccaud F., Falconnet C., Maillard M., Shamlaye C., Burnier M., 2005. Hypertension, 45 (3) pp. 445-450. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_4F47F1E4448A]

Influence de l'industrie sur les études concernant l'hypertension [Drug industry influence on hypertension treatment trials]

Waeber B., Burnier M., Pechère-Bertschi A., 2005. Revue médicale suisse, 1 (32) pp. 2067-8.

[Pmid][serval:BIB_A49AA278A521]

La prise en charge de l'hyper- tension artériette par des médecins en formation suit-elle les recommandations actuettes [Are the guidelines for the management of hypertensive patients followed by primary care residents and fellows?]

Birchmeier A., Favrat B., Burnier M., 2005. Revue médicale suisse, 1 (32) pp. 2081-2, 2084-6, 2088.

[Pmid][serval:BIB_F9118600B1F3]

Metoprolol prevents sodium retention induced by lower body negative pressure in healthy men.

Wuerzner G., Chiolero A., Maillard M., Nussberger J., Burnier M., 2005. Kidney International, 68 (2) pp. 688-694. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_027CDEC7DC4C]

Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients.

Teta D., Lüscher B.L., Gonvers J.J., Francioli P., Phan O., Burnier M., 2005. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 20 (5) pp. 991-3. Peer-reviewed.

[URN][DOI][WoS][Pmid][serval:BIB_7B8E77E45E33]

Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor.

Hasler C., Nussberger J., Maillard M., Forclaz A., Brunner H.R., Burnier M., 2005. Clinical pharmacology and therapeutics, 78 (5) pp. 501-7. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_2D64751E5DE9]

The CYP3A5 polymorphism is associated with ambulatory blood pressure increase with age in families of African descent

Bochud Murielle, Eap Chin-Bin, Elston Robert C., Bovet Pascal, Schild Laurent, Maillard Marc P., Burnier Michel, 2005. p. 367 dans , Journal of Hypertension. Peer-reviewed.

[serval:BIB_D82BF9E3E810]

The CYP3A5 polymorphism is associated with urinary sodium excretion in families of African descent

Bochud Murielle, Elston Robert C., Bovet Pascal, Schild Laurent, Maillard Marc P., Burnier Michel, Eap Chin-Bin, 2005. p. 364 dans , Journal of Hypertension. Peer-reviewed.

[serval:BIB_98D57AC04240]

2004

Efficacy of enzyme replacement therapy in Fabry disease.

Barbey F., Hayoz D., Widmer U., Burnier M., 2004/10. Current Medicinal Chemistry. Cardiovascular and Hematological Agents, 2 (4) pp. 277-286.

[Pmid][serval:BIB_A1B790CA0A88]

Female sex hormones, salt, and blood pressure regulation

Pechere-Bertschi A., Burnier M., 2004/10. American Journal of Hypertension, 17 (10) pp. 994-1001.

[URN][DOI][WoS][Pmid][serval:BIB_51C30638D587]

Cost-effectiveness of losartan versus atenolol in treating hypertension--an analysis of the LIFE study from a Swiss perspective

Szucs T. D., Burnier M., Erne P., 2004/09. Cardiovascular Drugs and Therapy, 18 (5) pp. 391-7.

[DOI][WoS][Pmid][serval:BIB_F4653BF5FD25]

Usefulness of artificial neural networks to predict follow-up dietary protein intake in hemodialysis patients

Gabutti L., Burnier M., Mombelli G., Male F., Pellegrini L., Marone C., 2004/07. Kidney International, 66 (1) pp. 399-407.

[DOI][WoS][Pmid][serval:BIB_C1D0500E4EDA]

Chronic hyperaldosteronism in a transgenic mouse model fails to induce cardiac remodeling and fibrosis under a normal-salt diet

Wang Q., Clement S., Gabbiani G., Horisberger J. D., Burnier M., Rossier B. C., Hummler E., 2004/06. American Journal of Physiology Renal Physiology, 286 (6) pp. F1178-84.

[DOI][WoS][Pmid][serval:BIB_F802E588109A]

Reasons for not intensifying antihypertensive treatment (RIAT): a primary care antihypertensive intervention study.

Ferrari P., Hess L., Pechere-Bertschi A., Muggli F., Burnier M., 2004/06. Journal of hypertension, 22 (6) pp. 1221-1229. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_7C6E84937A35]

Artificial neural networks improve the prediction of Kt/V, follow-up dietary protein intake and hypotension risk in haemodialysis patients

Gabutti L., Vadilonga D., Mombelli G., Burnier M., Marone C., 2004/05. Nephrology, Dialysis, Transplantation, 19 (5) pp. 1204-11.

[URN][DOI][WoS][Pmid][serval:BIB_D70A473B47CB]

Determination of cardiac contractility in awake unsedated mice with a fluid-filled catheter.

Wang Q., Brunner H.R., Burnier M., 2004/02. American Journal of Physiology. Heart and Circulatory Physiology, 286 (2) pp. H806-814. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_ACD019DA9769]

Angiotensin II receptor blockade prevents acute renal sodium retention induced by low levels of orthostatic stress.

Wuerzner G., Chioléro A., Maillard M., Nussberger J., Brunner H.R., Burnier M., Chiclero A., 2004. Kidney International, 65 (1) pp. 238-244. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_0ECD16DDBFAE]

Clinical Pharmacology of Angiotensin II Receptor Antagonists

Maillard M., Burnier M., 2004. pp. 453-484 dans Unger T., Schölkens B. A. (eds.) Handbook of Experimental Pharmacology, Springer.

[serval:BIB_2104B6F4F832]

Discordant prevalence of hypertension using two different automated blood pressure measurement devices: a population-based study in Dar es Salaam (Tanzania).

Chiolero A., Gervasoni J.P., Rwebogora A., Mkamba M., Waeber B., Paccaud F., Burnier M., Bovet P., 2004. Blood pressure monitoring, 9 (2) pp. 59-64. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_95E3F3C984A0]

Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men.

Zanchi A., Chiolero A., Maillard M., Nussberger J., Brunner H.R., Burnier M., 2004. Journal of Clinical Endocrinology and Metabolism, 89 (3) pp. 1140-1145. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_48EF40A166F5]

Gender difference in the response to an angiotensin-converting enzyme inhibitor and a diuretic in hypertensive patients of African descent.

Falconnet C., Bochud M., Bovet P., Maillard M., Burnier M., 2004. Journal of hypertension, 22 (6) pp. 1213-1220. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_496E6C44CAED]

Hyperoxaluries massives [Massive hyperoxaluria]

Barbey F., Cachat F., Nguyen Q.V., Rotman S., Burnier M., Daudon M., 2004. Revue médicale de la Suisse romande, 124 (8) pp. 477-82.

[Pmid][serval:BIB_B8BA1F261657]

Inhibiteurs de l'anhydrase carbonique et lithiase urinaire phosphocalcique [Carbonic anhydrase inhibitors and calcium phosphate stones].

Barbey F., Nseir G., Ferrier C., Burnier M., Daudon M., 2004. Néphrologie, 25 (5) pp. 169-172.

[WoS][Pmid][serval:BIB_0C6A38014BA8]

Lithiase urinaire [Urinary calculi].

Barbey F., Cachat F., Jichlinski P., Burnier M., 2004. Revue Médicale de la Suisse Romande, 124 (8) p. 432.

[Pmid][serval:BIB_73B35B0FCA26]

Patients' sibling history was sensitive for hypertension and specific for diabetes.

Bochud M., Burnier M., Paccaud F., Falconnet C., Mooser V., Both N., Bovet P., 2004. Journal of clinical epidemiology, 57 (5) pp. 497-501. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_EFD7DD0802C1]

Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country.

Conen D., Wietlisbach V., Bovet P., Shamlaye C., Riesen W., Paccaud F., Burnier M., 2004. BMC public health, 4 pp. 9 [9 p.]. Peer-reviewed.

[URN][DOI][WoS][Pmid][serval:BIB_837F12D8EDBA]

2003

A young man with a renal colic

Barbey F., Matthieu C., Nseir G., Burnier M., Teta D., 2003/12. Journal of Internal Medicine, 254 (6) pp. 605-8. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_EFE9C195BBE5]

Electronic monitoring of long-term use of the nicotine nasal spray and predictors of success in a smoking cessation program

Schneider M. P., van Melle G., Uldry C., Huynh-Ba M., Fallab Stubi C. L., Iorillo D., Burnier M., Zellweger J. P., 2003/10. Nicotine and Tobacco Research, 5 (5) pp. 719-27.

[DOI][WoS][Pmid][serval:BIB_E01CCF36E2A3]

Renal hemodynamic and tubular responses to salt in women using oral contraceptives

Pechere-Bertschi A., Maillard M., Stalder H., Bischof P., Fathi M., Brunner H. R., Burnier M., 2003/10. Kidney International, 64 (4) pp. 1374-80.

[DOI][WoS][Pmid][serval:BIB_07E550B14F53]

AT1-receptor antagonism in hypertension: what has been learned with irbesartan?

Waeber B., Burnier M., 2003/05. Expert Review of Cardiovascular Therapy, 1 (1) pp. 23-33.

[DOI][Pmid][serval:BIB_74208AC98170]

A pregnant woman with de novo polyuria-polydipsia and elevated liver enzymes.

Barbey F., Bonny O., Rothuizen L., Gomez F., Burnier M., 2003. Nephrology, Dialysis, Transplantation, 18 (10) pp. 2193-2196.

[URN][DOI][WoS][Pmid][serval:BIB_FDB08EEB13B0]

ALLHAT : les questions et les réponses d'une méga-étude dans le domaine de l'hypertenson artérielle

Waeber B., Burnier M., 2003. Médecine et Hygiène, 61 (2419) pp. 71-75.

[serval:BIB_0304CAE1875C]

Amerikanische und Europäische Hypertonie-Richtlinien: Welchen Auswirkungen haben die transatlantischen Differenzen in de Praxis ?

Chiolero A., Bovet P., Burnier M., 2003. Cardiovasc, 4 pp. 17-22.

[serval:BIB_73CAE6053C12]

Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor?

Forclaz A., Maillard M., Nussberger J., Brunner H.R., Burnier M., 2003. Hypertension, 41 (1) pp. 31-6.

[DOI][WoS][Pmid][serval:BIB_05B6875D84FC]

Appareils d'auto-mesure de la pression artérielle : quel appareil conseiller à nos patients ?

Santschi V., Forclaz A., Wuerzner G., de Clerck L., Chioléro A., Pechère A., Burnier M., 2003. Médecine et Hygiène, 61 (2432) pp. 766-772.

[serval:BIB_3DD37D32F17F]

Are cyclooxygenase-2-selective inhibitors safe for the kidneys?

Phan O., Meier P., Burnier M., 2003. Joint, Bone, Spine : Revue Du Rhumatisme, 70 (4) pp. 237-241.

[DOI][WoS][Pmid][serval:BIB_5228D1912A4A]

Assessing the prevalence of hypertension in populations: are we doing it right?

Bovet P., Gervasoni J.P., Ross A.G., Mkamba M., Mtasiwa D.M., Lengeler C., Burnier M., Paccaud F., 2003. Journal of hypertension, 21 (3) pp. 509-517. Peer-reviewed.

[URN][DOI][WoS][Pmid][serval:BIB_3FD5FC64AB17]

Comorbidité et facteurs de risque cardiovasculaire liés à l'insuffisance rénale chronique

Meier P., Saudan P., Burnier M., Martin P. Y., 2003. Médecine et Hygiène, 61 (2426) pp. 441-450.

[serval:BIB_C8EA7F02157C]

Conférence de consensus des experts suisses. Microalbuminurie : déterminer ce nouveau facteur de risque cardiovasculaire par le rapport albumine/créatinine

Burnier M., Von Eckardstein A., Hess Bm Lehmann R., Riesen W. F., Wuthrich R. P., 2003. Gériatrie Pratique, 2 pp. 1-4.

[serval:BIB_CE580EC3D7BD]

Difficult blood pressure control: watch out for non-compliance!

Wuerzner K., Hassler C., Burnier M., 2003. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 18 (10) pp. 1969-73. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_EBAC2630FF7B]

Dual transplant of marginal kidneys. Case report and review of the literature.

Matter M., Venetz J.P., Aubert V., Gachet C., Burnier M., Barbey F., 2003. Swiss Surgery = Schweizer Chirurgie = Chirurgie Suisse = Chirurgia Svizzera, 9 (5) pp. 213-215.

[Pmid][serval:BIB_29008]

Evaluation of online telemonitoring of drug adherence: a pilot randomized, controlled study in patients with epilepsy.

Schneider M.P, Despland P.A, Buclin Th., Burnier M, 2003. The Journal on Information Technology in Healthcare, 1(6) pp. 419-435.

[serval:BIB_29991]

First double renal transplants from adult marginal donors. Case report.

Matter M., Barbey F., Teta D., Burnier M., 2003. p. 3 dans Congrès Annuel de la Société Suisse de Chirurgie organisé en commun avec la Société Suisse de Chirurgie Thoracique et Cardio-Vasculaire, Swiss Surgery. Peer-reviewed.

[serval:BIB_6F30BC208D69]

L'hypertension artérielle : à l'ombre ou à la lumière des recommandations

Waeber B., Burnier M., 2003. Médecine et Hygiène, 61 p. 1667.

[serval:BIB_B74785CAFDDD]

L'hypertension artérielle : à l'ombre ou à la lumière des recommandations ?

Waeber B., Burnier M., 2003. Médecine et Hygiène, 61 p. 1667.

[serval:BIB_29195]

L'étude ALLHAT (Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial) : une fausse bonne nouvelle ?

Burnier M., 2003. Forum Médical Suisse 25 pp. 577-578.

[serval:BIB_9E7DAAA1B55F]

La fibrose rétropéritonéale, une maladie inflammatoire méconnue. Observations cliniques et revue de la littérature [Retroperitoneal fibrosis, an unrecognized inflammatory disease. Clinical observations and review of the literature]

Meier P., Gilabert C., Burnier M., Blanc E., 2003. Néphrologie, 24 (4) pp. 173-80. Peer-reviewed.

[WoS][Pmid][serval:BIB_A5091D789AB6]

La sensibilité au sel de la pression artérielle: un régime riche en sel est-il une cause de mort précoce ?

Chiolero A., Würzner G., Burnier M., 2003. Cardiovasc, 4 pp. 29-34.

[serval:BIB_17B18E3A0085]

Le paracétamol enlève la douleur sans mettre en danger le cœur. Attention aux AINS dans l’insuffisance cardiaque

Burnier M., 2003. Algia Intern, 5 pp. 11-12.

[serval:BIB_BFA1CD772104]

Le point sur le traitement de l'hypertension artérielle : que tirer des grandes études cliniques récentes

Burnier M., 2003. Médecine et Hygiène, 61 (2439) pp. 1145-1152.

[serval:BIB_5F6E7290CD0D]

Mesures de la pression artérielle en pharmacie : une évaluation des pratiques en Suisse romande

Bugnon O., Santschi V., Schwalm-Fayad V., Burnier M., 2003. Médecine et Hygiène, 61 (2449) pp. 1701-1704.

[serval:BIB_832002969D3C]

Modifications de certaines habitudes de vie reconnues dans la prise en charge non pharmacologique de l'hypertension artérielle

Meier P., Burnier M., 2003. Médecine et Hygiène, 61 (2449) pp. 1685-1693.

[serval:BIB_4D5BAFF44E2C]

Monitoring compliance in resistant hypertension: an important step in patient management.

Burnier M., Santschi V., Favrat B., Brunner H.R., 2003. Journal of Hypertension. Supplement, 21 (2) pp. S37-42.

[WoS][Pmid][serval:BIB_58811CED97AE]

Qu'en est-il de la tolérance rénale des Coxibs ?

Phan O., Meier P., Burnier M., 2003. Revue du Rhumatisme, 70 pp. 545-549.

[serval:BIB_9A077915682C]

Quand commence le rôle du néphrologue

Martin P. Y., Burnier M., 2003. Médecine et Hygiène, 61 pp. 435-446.

[serval:BIB_6713F6DA7A3A]

Recent clinical trials with omapatrilat: new developments.

Zanchi A., Maillard M., Burnier M., 2003. Current hypertension reports, 5 (4) pp. 346-52. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_29842]

Recommandations américaines et européennes pour la prise en charge de patients hypertendus : quel impact pour la pratique ?

Chioléro A., Bovet P., Burnier M., 2003. Médecine et Hygiène, 61 (2449) pp. 1670-1676.

[serval:BIB_E9E9D8E5415D]

Rythme circadien de la tension artérielle et chronothérapie

Hasler C., Burnier M., 2003. Médecine et Hygiène, 61 (2449) pp. 1694-1698.

[serval:BIB_1C1E8F9D0536]

The pitfall of informed consent in clinical research

Burnier M., 2003. Patient's network, 18 pp. 18-19.

[serval:BIB_98AA73C8D815]

Y aura-t-il bientôt aussi des "préhypertendus " en Suisse ?

Burnier M., 2003. Cardiovasc, 4 p. 1.

[serval:BIB_7721A7F65DFA]

2002

In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist

Maillard M. P., Perregaux C., Centeno C., Stangier J., Wienen W., Brunner H. R., Burnier M., 2002/09. Journal of Pharmacology and Experimental Therapeutics, 302 (3) pp. 1089-95.

[DOI][WoS][Pmid][serval:BIB_9982F6DDA667]

Maladie de Fabry: du diagnostic a l'enzymotherapie substitutive. [Fabry disease: diagnostic due of substitutive enzyme-therapy]

Barbey F., Widmer U., Burnier M., Lidove O., 2002/09. Revue Médicale de la Suisse Romande, 122 (9) pp. 449-53.

[Pmid][serval:BIB_4FB6E730B695]

Postischemic forearm skin reactive hyperemia is related to cardovascular risk factors in a healthy female population

Vuilleumier P., Decosterd D., Maillard M., Burnier M., Hayoz D., 2002/09. Journal of Hypertension, 20 (9) pp. 1753-7.

[DOI][WoS][Pmid][serval:BIB_05BE10A65979]

Hyperuricemia, hypertension, and proteinuria associated with high-altitude polycythemia.

Jefferson J.A., Escudero E., Hurtado M.E., Kelly J.P., Swenson E.R., Wener M.H., Burnier M., Maillard M., Schreiner G.F., Schoene R.B. et al., 2002/06. American Journal of Kidney Diseases, 39 (6) pp. 1135-1142.

[DOI][WoS][Pmid][serval:BIB_66BC783DCB42]

Cardiovascular hazard of selective COX-2 inhibitors: myth or reality?

Chiolero A., Maillard M.P., Burnier M., 2002/05. Expert opinion on drug safety, 1 (1) pp. 45-52. Peer-reviewed.

[Pmid][serval:BIB_25296]

L'observance therapeutique, un element cle de la prise en charge de l'hypertension arterielle. [Treatment compliance, key element in the management of arterial hypertension]

Chiolero A., Santschi V., Burnier M., 2002/05. Revue Médicale de la Suisse Romande, 122 (5) pp. 237-40.

[Pmid][serval:BIB_2708ABFBF49B]

Renal segmental tubular response to salt during the normal menstrual cycle

Pechere-Bertschi A., Maillard M., Stalder H., Brunner H. R., Burnier M., 2002/02. Kidney International, 61 (2) pp. 425-31.

[DOI][WoS][Pmid][serval:BIB_E46224981D4E]

Blood pressure control and the implementation of guidelines in clinical practice: can we fill the gap?

Burnier M., 2002. Journal of hypertension, 20 (7) pp. 1251-3. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_C1BB3465B319]

Blood pressure, cardiac, and renal responses to salt and deoxycorticosterone acetate in mice: role of Renin genes.

Wang Q., Hummler E., Nussberger J., Clément S., Gabbiani G., Brunner H.R., Burnier M., 2002. Journal of the American Society of Nephrology, 13 (6) pp. 1509-1516. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_CBE4E8F323D6]

Body mass index, abdominal adiposity and blood pressure: consistency of their association across developing and developed countries.

Doll S., Paccaud F., Bovet P., Burnier M., Wietlisbach V., 2002. International journal of obesity and related metabolic disorders, 26 (1) pp. 48-57. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_3BA5BA68AA99]

Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing.

Maillard M.P., Würzner G., Nussberger J., Centeno C., Burnier M., Brunner H.R., 2002. Clinical pharmacology and therapeutics, 71 (1) pp. 68-76. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_1FABE58ED78C]

Du nouveau dans la prise en charge du malade hypertendu avec diabète de type 2

Waeber B., Feihl F., Burnier M., 2002. Médecine et Hygiène, 60 pp. 105-109.

[serval:BIB_99315667B479]

Hypertension--observance thérapeutique: de l'impression du médecin à la télémétrie [Hypertension -- therapeutic observation: the medical impression of telemetry]

Burnier M., Santschi V., Fallab-Stubi C.L., Chiolero A., Schneider M.P., Favrat B., 2002. Revue médicale de la Suisse romande, 122 (10) pp. 467-70.

[Pmid][serval:BIB_496CCBB3F718]

Implications physiopathologiques et cliniques des recepteurs AT(1)/AT(2) de l'angiotensine II dans l'hypertension essentielle. [Pathophysiological and clinical implications of AT(1) and AT(2) angiotensin II receptors in essential hypertension]

Burnier M., 2002. Drugs, 62 Spec No 1 pp. 21-9.

[DOI][WoS][Pmid][serval:BIB_42A037B280D5]

Monitoring one-year compliance to antihypertension medication in the Seychelles.

Bovet P., Burnier M., Madeleine G., Waeber B., Paccaud F., 2002. Bulletin of the World Health Organization, 80 (1) pp. 33-9. Peer-reviewed.

[WoS][Pmid][serval:BIB_C940D2A39AE2]

Renal hemodynamic and natriuretic effects of concomitant Angiotensin-converting enzyme and neutral endopeptidase inhibition in men.

Regamey F., Maillard M., Nussberger J., Brunner H.R., Burnier M., 2002. Hypertension, 40 (3) pp. 266-72.

[DOI][WoS][Pmid][serval:BIB_7B98175BFE96]

2001

Antihypertensive treatment and compliance. Study was too short and lacked active intervention

Burnier M., Brunner H. R., 2001/11. BMJ, 323 (7321) pp. 1129; author reply 1130. Peer-reviewed.

[WoS][Pmid][serval:BIB_3E8EFE046B7E]

Dose protein binding modulate the effect of angiotensin II receptor antagonists

Maillard MP, Centeno C, Frostell-Karlsson A, Brunner HR, Burnier M, 2001/03. Journal of the Renin-Angiotensin-Aldosterone System, 2 (Suppl 1) pp. S54-S58.

[serval:BIB_D323A63F5185]

Angiotensin II type 1 receptor blockers

Burnier M., 2001/02. Circulation, 103 (6) pp. 904-12.

[WoS][Pmid][serval:BIB_9D45D4FE852E]

Angiotensin II receptor antagonists: safety and tolerability profile.

Mazzolai L., Burnier M., 2001. pp. 339-350 dans Epstein M., Brunner H.R. (eds.) Angiotensin II Receptor Antagonists, Hanley & Belfus.

[serval:BIB_81F12D2B5F4D]

Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout.

Würzner G., Gerster J.C., Chiolero A., Maillard M., Fallab-Stubi C.L., Brunner H.R., Burnier M., 2001. Journal of Hypertension, 19 (10) pp. 1855-1860. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_5B4CD494901A]

Compensatory up-regulation of angiotensin II subtype 1 receptors in alpha ENaC knockout heterozygous mice.

Wang Q., Hummler E., Maillard M., Nussberger J., Rossier B.C., Brunner H.R., Burnier M., 2001. Kidney international, 59 (6) pp. 2216-21. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_F0A2E0EC7B39]

Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions.

Burnier M., Schneider M.P., Chioléro A., Stubi C.L., Brunner H.R., 2001. Journal of hypertension, 19 (2) pp. 335-41. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_05568F8E8662]

Novel angiotensin II inhibitors in cardiovascular medicine.

Burnier M., 2001. Expert opinion on investigational drugs, 10 (11) pp. 1957-64. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_6BB0A4D82985]

Renal and neurohormonal responses to increasing levels of lower body negative pressure in men.

Würzner G., Chiolero A., Maillard M., Nussberger J., Hayoz D., Brunner H.R., Burnier M., 2001. Kidney international, 60 (4) pp. 1469-76. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_619256814E32]

Renal determinants of the salt sensitivity of blood pressure.

Chiolero A., Würzner G., Burnier M., 2001. Nephrology, Dialysis, Transplantation, 16 (3) pp. 452-458. Peer-reviewed.

[URN][DOI][WoS][Pmid][serval:BIB_ABF1F91CCE24]

Serum uric acid, losartan, and the metabolic syndrome

Burnier M., Wuerzner G., Conen D., 2001. Receptors in Cardiovascular Disease 11 pp. 1-5.

[serval:BIB_A47445D52168]

The comparative pharmacology of angiotensin II receptor antagonists

Burnier M., Maillard M., 2001. Blood Pressure. Supplement, 1 pp. 6-11.

[Pmid][serval:BIB_CEA09BED9524]

The return of increased blood pressure after discontinuation of antihypertensive treatment is associated with an impaired post-ischemic skin blood flow response.

Sieg-Dobrescu D., Burnier M., Hayoz D., Brunner H.R., Waeber B., 2001. Journal of hypertension, 19 (8) pp. 1387-92. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_3B0BEB17CB0C]

Traitement de l'hypertension et prévention de la néphropathie dans le diabète de type 2

Wuerzner G., Burnier M., 2001. Médecine et Hygiène, 59 (2359) pp. 1719-1724.

[serval:BIB_0E4F7766FC3A]

2000

Blood pressure and renal haemodynamic response to salt during the normal menstrual cycle.

Pechère-Bertschi A., Maillard M., Stalder H., Brunner H.R., Burnier M., 2000/06. Clinical Science, 98 (6) pp. 697-702. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_C3C2F4E30AC9]

Angiotensin II receptor antagonists: where do we stand?

Burnier M., Maillard M., 2000/03. IDrugs, 3 (3) pp. 304-9.

[Pmid][serval:BIB_30B1FBA2DEF6]

Angiotensin II receptor antagonists

Burnier M., Brunner H. R., 2000/02. Lancet, 355 (9204) pp. 637-45.

[DOI][WoS][Pmid][serval:BIB_50C4A9A0887B]

Salt- and angiotensin II-dependent variations in amiloride-sensitive rectal potential difference in mice

Wang Q., Horisberger J. D., Maillard M., Brunner H. R., Rossier B. C., Burnier M., 2000/02. Clinical and Experimental Pharmacology and Physiology, 27 (1-2) pp. 60-6.

[DOI][WoS][Pmid][serval:BIB_01D76E838565]

Angiotensin II receptor blockers: will they replace or add to angiotensin converting enzyme inhibitors ?

Burnier M., Brunner H.R., 2000. pp. 133-152 dans Kaplan N. M. (eds.) Hypertension Therapy Annual, Martin Dunitz Ltd.

[serval:BIB_16753]

Antagonistes de l'angiotensine II et acide urique

Burnier M., 2000. pp. 48-51 dans H. R. Brunner , W. Vetter (eds.) Les antagonistes de l'angiotensine II au centre de l'intérêt dans la thérapie rationelle de l'hypertension et de ses complications, ZETT-Verlag.

[serval:BIB_9062C98FF3BA]

Effect of SR 49059, a V1a vasopressin receptor antagonist, in Raynaud's phenomenon.

Hayoz D., Bizzini G., Noël B., Depairon M., Burnier M., Fauveau C., Rouillon A., Brouard R., Brunner H.R., 2000. Rheumatology, 39 (10) pp. 1132-1138. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_E30346AE93FE]

How to improve adherence with prescribed treatment in hypertensive patients?

Waeber B., Burnier M., Brunner H.R., 2000. Journal of cardiovascular pharmacology, 35 Suppl 3 pp. S23-S26. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_7D7647DBC55D]

Improving hypertension control through increased adherence

Burnier M., Wuerzner G., Schneider M.P., 2000. pp. 123-129 dans Sleight P. (eds.) Clinical Cases in Hypertension: Specific Treatment Strategies, PAN Communications.

[serval:BIB_E8F91E4320A0]

Is nurse-measured blood pressure a valid substitute for ambulatory blood pressure monitoring?

Gerc V., Favrat B., Brunner H.R., Burnier M., 2000. Blood pressure monitoring, 5 (4) pp. 203-9. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_6B1FBD2DE4CA]

Les inhibiteurs sélectifs de la cyclooxygénase de type 2: moins d'effets rénaux que les anti-inflammatoires non stéroïdiens classiques [Selective inhibitors of type 2 cyclooxygenase: less renal effects than the classical non-steroidal anti-inflammatory agents].

Chiolero A., Würzner G., Burnier M., 2000. Néphrologie, 21 (8) pp. 425-430.

[WoS][Pmid][serval:BIB_24E1FFB23B91]

Long-term compliance with antihypertensive therapy: another facet of chronotherapeutics in hypertension

Burnier M., 2000. Blood Pressure Monitoring, 5 Suppl 1 pp. S31-4.

[DOI][WoS][Pmid][serval:BIB_A3982AAD1BCD]

Microalbuminurie et hypertension

Wuerzner G., Chiolero A, Burnier M., 2000. Hypertension, 12 (3) pp. 361-65.

[serval:BIB_338A6716D8C4]

Pharmacologic profile of UR-7247, an orally active angiotensin II AT1 receptor antagonist, in healthy volunteers. p6.

Maillard M.P., Rossat J., Nussberger J., Ramis J., Pontes C., Burnier M., Brunner H.R., 2000. Journal of cardiovascular pharmacology, 35 (3) pp. 383-9. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_85DFCAEE0A76]

Pharmacologie des antagonistes des récepteurs AT1 de l'angiotensine II

Burnier M., Wuerzner G., 2000. Médecine et Hygiène, 58 (2305) pp. S8-S11.

[serval:BIB_02137EBFCE9A]

Prise en charge de l'hypertension: quoi de neuf?

Wuerzner G., Burnier M., 2000. Tribuna Medica Ticinese 65 pp. 85-89.

[serval:BIB_6BEC63B9869A]

Proximal sodium reabsorption: An independent determinant of blood pressure response to salt.

Chiolero A., Maillard M., Nussberger J., Brunner H.R., Burnier M., 2000. Hypertension, 36 (4) pp. 631-7.

[WoS][Pmid][serval:BIB_C30DB52DD7EE]

Renal sodium handling in acute and chronic salt loading/depletion protocols: the confounding influence of acute water loading.

Burnier M., Monod M.L., Chioléro A., Maillard M., Nussberger J., Brunner H.R., 2000. Journal of hypertension, 18 (11) pp. 1657-64. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_5FEEF37431FC]

Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding.

Maillard M.P., Rossat J., Brunner H.R., Burnier M., 2000. The Journal of pharmacology and experimental therapeutics, 295 (2) pp. 649-54. Peer-reviewed.

[WoS][Pmid][serval:BIB_5B488D26D770]

Why Objective Monitoring of Compliance is Important in the Management of Hypertension.

Bertholet N., Favrat B., Fallab-Stubi C.L., Brunner H.R., Burnier M., 2000. Journal of Clinical Hypertension, 2 (4) pp. 258-262.

[Pmid][serval:BIB_8DB0B24F6893]

1999

A mouse model for Liddle's syndrome

Pradervand S., Wang Q., Burnier M., Beermann F., Horisberger J. D., Hummler E., Rossier B. C., 1999/12. Journal of the American Society of Nephrology, 10 (12) pp. 2527-33.

[WoS][Pmid][serval:BIB_27A74C9C2D1D]

Compliance with antihypertensive therapy.

Waeber B., Burnier M., Brunner H.R., 1999/08. Clinical and Experimental Hypertension, 21 (5-6) pp. 973-985. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_A8EFD6196B27]

Comparative safety and tolerability of angiotensin II receptor antagonists

Mazzolai L., Burnier M., 1999/07. Drug Safety, 21 (1) pp. 23-33.

[DOI][WoS][Pmid][serval:BIB_E5A1DB4B97E2]

Comparative antihypertensive effects of angiotensin II receptor antagonists

Burnier M., Brunner H. R., 1999/04. Journal of the American Society of Nephrology, 10 Suppl 12 pp. S278-82.

[WoS][Pmid][serval:BIB_A61BD40697EB]

Adducin polymorphism affects renal proximal tubule reabsorption in hypertension

Manunta P., Burnier M., D'Amico M., Buzzi L., Maillard M., Barlassina C., Lanella G., Cusi D., Bianchi G., 1999/02. Hypertension, 33 (2) pp. 694-7.

[WoS][Pmid][serval:BIB_AD8AE61ADFDA]

Salt restriction induces pseudohypoaldosteronism type 1 in mice expressing low levels of the beta-subunit of the amiloride-sensitive epithelial sodium channel

Pradervand S., Barker P. M., Wang Q., Ernst S. A., Beermann F., Grubb B. R., Burnier M., Schmidt A., Bindels R. J., Gatzy J. T. et al., 1999/02. Proceedings of the National Academy of Sciences of the United States of America, 96 (4) pp. 1732-37. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_C019CA31E6AD]

[Does constitutional hypotension exist?]

Pechere-Bertschi A., Nussberger J., Burnier M., 1999/01. Therapeutische Umschau, 56 (1) pp. 49-54.

[Pmid][serval:BIB_F0FB3259272B]

Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists.

Mazzolai L., Maillard M., Rossat J., Nussberger J., Brunner H.R., Burnier M., 1999. Hypertension, 33 (3) pp. 850-5. Peer-reviewed.

[WoS][Pmid][serval:BIB_7A8B77785129]

Assessment of angiotensin II receptor blockade in humans using a standardized angiotensin II receptor-binding assay.

Maillard M.P., Mazzolai L., Daven V., Centeno C., Nussberger J., Brunner H.R., Burnier M., 1999. American journal of hypertension, 12 (12 Pt 1-2) pp. 1201-8. Peer-reviewed.

[URN][DOI][WoS][Pmid][serval:BIB_5EE756EA6CCB]

Electronic monitoring of compliance to lipid-lowering therapy in clinical practice.

Schwed A., Fallab C.L., Burnier M., Waeber B., Kappenberger L., Burnand B., Darioli R., 1999. Journal of Clinical Pharmacology, 39 (4) pp. 402-409. Peer-reviewed.

[URN][DOI][WoS][Pmid][serval:BIB_12707]

Le point sur le traitement de l'hypertension arterielle [The goal in treating arterial hypertension]

Waeber B., Burnier M., Brunner H.R., 1999/01. Schweizerische medizinische Wochenschrift, 129 (1-2) pp. 14-16. Peer-reviewed.

[WoS][Pmid][serval:BIB_1817E228FCB4]

Les inhibiteurs de l'enzyme de conversion de l'angiotensine

40. Burnier M. Mazzolai L., 1999. Cardioscopie, 72 (270).

[serval:BIB_F4D8F4CC7798]

Medizin im Gespräch. Bedeutung der elektronischen Compliance-Kontrolle.

Burnier M., Würzner G., Chioléro A., Schneider M.P., 1999. Herz Kreislauf, 31 (Suppl. 1) pp. 20-23. Peer-reviewed.

[WoS][serval:BIB_12484]

Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects.

Burnier M., Fricker A.F., Hayoz D., Nussberger J., Brunner H.R., 1999. European journal of clinical pharmacology, 55 (9) pp. 633-7. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_3C8E35FC3287]

Place des antagonistes des récepteurs AT1 dans le traitement de l'hypertension artérielle

Chiolero A., Wuerzner G., Burnier M., Brunner H.R., 1999. Médecine et Hygiene, 57 (2267) pp. 1631-1634.

[serval:BIB_0E8974547D00]

Rational prescribing in suboptimal compliance

Waeber B., Burnier M., Brunner H. R., 1999. pp. 147-155 dans J. M. Métry , U. A. Meyer (eds.) Drug Regimen Compliance: Issues in Clinical Trials and Patient Management, John Wiley & Sons Ltd.

[serval:BIB_F21196A9697D]

Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects.

Rossat J., Maillard M., Nussberger J., Brunner H.R., Burnier M., 1999. Clinical pharmacology and therapeutics, 66 (1) pp. 76-84. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_75E5C403C413]

The place of microelectronic systems in measuring compliance

Schneider M. P., Fallab-Stubi C. L., Waeber B., Burnier M., 1999. pp. 85-96 dans J. M. Métry , U. A. Meyer (eds.) Drug Regimen Compliance: Issues in Clinical Trials and Patient Management, John Wiley & Sons Ltd.

[serval:BIB_F36C97E6DD0F]

1998

Angiotensin II receptor antagonists in hypertension

Burnier M., Brunner H. R., 1998/12. Kidney International. Supplement, 68 pp. S107-11.

[Pmid][serval:BIB_A291601EB18F]

Sodium balance and hypertension: rare genetic disorders expose pathogenic mechanisms

Burnier M., 1998/12. Experimental Nephrology, 6 (6) pp. 496-501.

[WoS][Pmid][serval:BIB_79EBB3C5097F]

On-line home monitoring of drug compliance: is it feasible?

Schneider M. P., Burnier M., 1998/08. European Journal of Clinical Pharmacology, 54 (6) pp. 489-90.

[DOI][WoS][Pmid][serval:BIB_7BA820F43AB3]

Electronic monitoring of adherence to treatment in the preventive chemotherapy of tuberculosis

Fallab-Stubi C. L., Zellweger J. P., Sauty A., Uldry C., Iorillo D., Burnier M., 1998/07. International Journal of Tuberculosis and Lung Disease, 2 (7) pp. 525-30.

[WoS][Pmid][serval:BIB_610AB5936401]

Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients

Minghelli G., Seydoux C., Goy J. J., Burnier M., 1998/07. Transplantation, 66 (2) pp. 268-71.

[DOI][WoS][Pmid][serval:BIB_CAAC5F477880]

Estimation of glomerular filtration rate by sinistrin clearance using various approaches

Buclin T., Sechaud R., Bertschi A. P., Decosterd L. A., Belaz N., Appenzeller M., Burnier M., Biollaz J., 1998/03. Renal Failure, 20 (2) pp. 267-76.

[DOI][WoS][Pmid][serval:BIB_BE2A0C977A87]

Effect of indomethacin on the renal response to angiotensin II receptor blockade in healthy subjects.

Fricker A.F., Nussberger J., Meilenbrock S., Brunner H.R., Burnier M., 1998. Kidney international, 54 (6) pp. 2089-97. Peer-reviewed.

[DOI][WoS][Pmid][serval:BIB_A519C63983E5]

Evaluation of the use of ultrasonography in primary care.

Decrey H, Verdon F, Burnand B, Pécoud A, Burnier M, 1998. European Journal of Public Health, 8 pp. 140-142.

[URN][DOI][WoS][serval:BIB_7043]

Pharmacology of valsartan, an angiotensin II receptor antagonist.

Chioléro A., Burnier M., 1998. Expert opinion on investigational drugs, 7 (11) pp. 1915-25.

[DOI][Pmid][serval:BIB_FA38A061573C]

1997

Effects of SR 49059, a new orally active and specific vasopressin V1 receptor antagonist, on vasopressin-induced vasoconstriction in humans

Weber R., Pechere-Bertschi A., Hayoz D., Gerc V., Brouard R., Lahmy J. P., Brunner H. R., Burnier M., 1997/11. Hypertension, 30 (5) pp. 1121-7.

[WoS][Pmid][serval:BIB_39BE78C8506E]

A mouse model for the renal salt-wasting syndrome pseudohypoaldosteronism

Hummler E., Barker P., Talbot C., Wang Q., Verdumo C., Grubb B., Gatzy J., Burnier M., Horisberger J. D., Beermann F. et al., 1997/10. Proceedings of the National Academy of Sciences of the United States of America, 94 (21) pp. 11710-15.

[DOI][WoS][Pmid][serval:BIB_0959ECAEEC92]

Sinistrin clearance for determination of glomerular filtration rate: a reappraisal of various approaches using a new analytical method

Buclin T., Pechere-Bertschi A., Sechaud R., Decosterd L. A., Munafo A., Burnier M., Biollaz J., 1997/08. Journal of Clinical Pharmacology, 37 (8) pp. 679-92.

[DOI][WoS][Pmid][serval:BIB_4EB67937BDCA]

Differentiation entre erythrocyturie glomerulaire et non-glomerulaire: quelle utilite pour le diagnostic differentiel des microhematuries? [Differentiation between glomerular and non-glomerular erythrocyturia: what is the value of differential microhematuria diagnosis?]

Gerc V., Schubert A., Burnier M., 1997/07. Schweizerische Rundschau fur Medizin Praxis, 86 (31-32) pp. 1198-203.

[Pmid][serval:BIB_5A5ED3A0B9B2]

Manifestations renales des affections virales. [Renal manifestations of viral diseases]

Pechere-Bertschi A., Burnier M., 1997/07. Schweizerische Rundschau fur Medizin Praxis, 86 (31-32) pp. 1204-8.

[Pmid][serval:BIB_8E0347C52EAA]

Nouveautes en nephrologie ambulatoire. [Innovations in ambulatory nephrology]

Burnier M., 1997/07. Schweizerische Rundschau fur Medizin Praxis, 86 (31-32) p. 1193.

[Pmid][serval:BIB_677C7F157415]

Angiotensin II receptor antagonists - antihypertensive agents.

Burnier M., Brunner H.R., 1997/05. Expert Opinion on Investigational Drugs, 6 (5) pp. 489-500.

[DOI][Pmid][serval:BIB_19A8D14E98EC]

Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11

Contact
Annuaires

Informations légales
Plan du site
Edition